BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 510 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 510 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total value of $37,898.10. Following the sale, the chief accounting officer owned 123,945 shares in the company, valued at approximately $9,210,352.95. The trade was a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Maricel Apuli also recently made the following trade(s):

• On Monday, December 8th, Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.26, for a total transaction of $148,520.00.

BridgeBio Pharma Price Performance

Shares of NASDAQ BBIO traded down $1.92 on Wednesday, hitting $73.93. The company’s stock had a trading volume of 2,365,520 shares, compared to its average volume of 3,243,876. The stock has a 50 day moving average of $75.70 and a 200-day moving average of $63.72. The company has a market capitalization of $14.25 billion, a price-to-earnings ratio of -17.69 and a beta of 1.13. BridgeBio Pharma, Inc. has a 12-month low of $28.33 and a 12-month high of $84.94.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $100 and reiterated a Buy rating, signaling bullish analyst support that could underpin the stock. Benzinga
• Positive Sentiment: Several Wall Street firms maintain buy/overweight ratings and a median 6‑month target near $94, providing analyst-driven upside thesis for investors focused on BBIO’s pipeline and long-term growth. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results after the close on Feb. 24 and host a 4:30 pm ET conference call — an event that can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to 34 new employees (76,701 aggregate shares) under Nasdaq rules; vesting schedules could modestly increase share-based compensation and future float. Inducement Grants
• Negative Sentiment: Multiple senior insiders sold stock on Feb. 17: Director Randal W. Scott (10,000 shares). These disclosed Form 4s reduce insider ownership and can spook investors when clustered. Scott Form 4
• Negative Sentiment: CFO Thomas Trimarchi sold 13,600 shares (≈$1.02M) and CAO Maricel Apuli sold 510 shares; clustered executive selling raises near‑term governance/ownership concerns for some investors. Trimarchi Form 4 Apuli Form 4
• Negative Sentiment: Data providers note a long history of insider sales (many officers have sold substantial blocks over recent months), which can weigh on sentiment even as analysts remain constructive. Insider/Analyst Summary

Institutional Investors Weigh In On BridgeBio Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in BBIO. Global Retirement Partners LLC lifted its stake in shares of BridgeBio Pharma by 271.5% in the 4th quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock valued at $39,000 after purchasing an additional 372 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after acquiring an additional 245 shares during the period. Kemnay Advisory Services Inc. acquired a new position in shares of BridgeBio Pharma during the 4th quarter valued at $41,000. Cary Street Partners Investment Advisory LLC boosted its position in BridgeBio Pharma by 861.0% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 567 shares of the company’s stock worth $43,000 after purchasing an additional 508 shares during the period. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in BridgeBio Pharma in the 4th quarter valued at $44,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on BBIO. Sanford C. Bernstein started coverage on shares of BridgeBio Pharma in a research report on Thursday, December 11th. They issued an “outperform” rating and a $94.00 price objective for the company. HC Wainwright increased their price target on BridgeBio Pharma from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday. Raymond James Financial set a $89.00 price objective on BridgeBio Pharma and gave the company an “outperform” rating in a research report on Thursday, February 12th. Piper Sandler upped their target price on BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Finally, Wells Fargo & Company increased their target price on BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.05.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.